Actavis 2 600

Sinapse has recently been awarded the tender to outsource Global Pharmaceutical Company, Actavis Australian IT Services.  

The services being outsourced include IT Infrastructure management, Help Desk and Applications Management & Support.

Sinapse has had a long working association with Actavis, having recently successfully completed a major Veeva ( CRM implementation for the business and providing Level 2 and Level 3 Veeva application support.

Sinapse will be working very closely and under the direction of the Actavis Global IT team.  Actavis believe this change will result in improved service levels to the business and will allow them access to a team of specialists providing their company with a greater depth of expertise.

Sheani De Silva, Sinapse Service Delivery Manager and previously Head of IT at GSK said "Actavis is a great client and we are really excited about extending our IT and Applications Support capability to such a large organisation.  This follows on from great Applications Support work we do with Celegene, Toyota and supporting Athena Softwares' 50 clients and 1,500 Penelope users in ANZ.  we partner with our diverse network of IT partners to take away the  hassle of running IT internally so organisations can focus budgets and resources on their core business growth.

"We have worked with Actavis for over 2  years now and previously with Ascent Pharmaceuticals prior to their purchase by Actavis", Soula Skliros, Sinapse Partner for Actavis commented.  "Acatvis and Sinapse have a great working relationship as had been evidenced in a number of successful engagements with their Australian and Global IT teams.  Sinapse brings specialist IT, systems integration, applications support and implementation services to Actavis.  Actavis wanted to take away take away the  hassle of running IT internally so they can focus their budgets and resources on their core business growth.  Sinapse was a natural fit to their requirements".





Actavis plc (NYSE:ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. FY13 market cap is $36.6b, with 19,000 employees.

Actavis markets generic brand, branded generic, legacy brands and Over-the-Counter (OTC) products in more than 60 countries. Our North American branded global branded specialty pharmaceutical business develops and markets a portfolio of products principally in the United States and Canada focused in the Urology, Women’s Health, Gastroenterology, and Dermatology therapeutic categories. Through internal development activities and in collaboration with Amgen, we are also developing biosimilars in Women’s Health, Oncology and other therapeutic categories. In addition, Actavis is the fourth-largest U.S. generic pharmaceutical product distributor through our Anda, Inc. business, and we also develop and out-license generic pharmaceutical products outside of the U.S. through our Medis third-party business.